EICHOR
● Active Not Recruiting
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Condition: Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer · Hot Flashes · Sponsor: Bayer
About this study
Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer therapy. VMS, also called hot flashes, are very common medical problems in women with hormone-receptor (HR)-positive breast cancer, who are receiving anti-cancer therapy. HR-positive breast cancer is a type of breast cancer, which has hormone-receptors (proteins) for female sex hormones estrogen and/or progesterone. These hormone-receptors may attach to hormones like estrogen and progesterone and thereby help cancer cells to grow and to spread. Treatments that stop these hormones from attaching to these receptors are currently used to slow or stop the growth of HR-positive breast cancer. It is already known that women with HR-positive breast cancer benefit from this treatment. However, hot flashes are common medical problems related to this therapy. They negatively affect quality of life of many women and may lead to discontinuation (stopping) of this therapy. The study treatment, elinzanetant is being developed to treat hot flushes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. The main purpose of this study is to learn more about how well elinzanetant helps to treat hot flashes caused by anti-cancer therapy in women with or at high risk for…
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (102)
| AKH Wien | Allg. Gynaekologie & gynaekologische Onkologie | Vienna, Burgenland, Austria | — |
| MedUni Innsbruck | Brust Gesundheit Zentrum | Vienna, State of Vienna, Austria | — |
| Medical University of Graz | Division of Gynecology and Obstetrics | Salzburg, Austria | — |
| ZAS Augustinus - Gynaecology department | Wilrijk, Antwerpen, Belgium | — |
| Hôpital Erasme/Erasmus Ziekenhuis | Brussels, Belgium | — |
| CHU Saint-Pierre/UMC Sint-Pieter | Bruxelles - Brussel, Belgium | — |
| CU Saint-Luc/UZ St-Luc | Bruxelles - Brussel, Belgium | — |
| Ziekenhuis Oost-Limburg - Gynecology Department | Genk, Belgium | — |
| Ghent University Hospital | Women's Clinic Department | Ghent, Belgium | — |
| UZ Leuven Gasthuisberg | Leuven, Belgium | — |
| Femicare vzw | Tienen, BE | Tienen, Belgium | — |
| The Ottawa Hospital - Riverside Campus | Ottawa, Ontario, Canada | — |
+ 90 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05587296